276 related articles for article (PubMed ID: 23000076)
1. Cannabinoid CB₁ receptor in the modulation of stress coping behavior in mice: the role of serotonin and different forebrain neuronal subpopulations.
Häring M; Grieb M; Monory K; Lutz B; Moreira FA
Neuropharmacology; 2013 Feb; 65():83-9. PubMed ID: 23000076
[TBL] [Abstract][Full Text] [Related]
2. Delta(9)-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test: involvement of cannabinoid CB(1) receptor and serotonergic system.
Egashira N; Matsuda T; Koushi E; Higashihara F; Mishima K; Chidori S; Hasebe N; Iwasaki K; Nishimura R; Oishi R; Fujiwara M
Eur J Pharmacol; 2008 Jul; 589(1-3):117-21. PubMed ID: 18565508
[TBL] [Abstract][Full Text] [Related]
3. Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice.
Dubreucq S; Matias I; Cardinal P; Häring M; Lutz B; Marsicano G; Chaouloff F
Neuropsychopharmacology; 2012 Jul; 37(8):1885-900. PubMed ID: 22434220
[TBL] [Abstract][Full Text] [Related]
4. Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling.
Kamprath K; Plendl W; Marsicano G; Deussing JM; Wurst W; Lutz B; Wotjak CT
Genes Brain Behav; 2009 Mar; 8(2):203-11. PubMed ID: 19077175
[TBL] [Abstract][Full Text] [Related]
5. Effect of delta-9-tetrahydrocannabinol on behavioral despair and on pre- and postsynaptic serotonergic transmission.
Bambico FR; Hattan PR; Garant JP; Gobbi G
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jul; 38(1):88-96. PubMed ID: 22386778
[TBL] [Abstract][Full Text] [Related]
6. Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons.
Sano K; Mishima K; Koushi E; Orito K; Egashira N; Irie K; Takasaki K; Katsurabayashi S; Iwasaki K; Uchida N; Egawa T; Kitamura Y; Nishimura R; Fujiwara M
Neuroscience; 2008 Jan; 151(2):320-8. PubMed ID: 18083311
[TBL] [Abstract][Full Text] [Related]
7. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
Darmani NA; Johnson JC
Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
[TBL] [Abstract][Full Text] [Related]
8. Bimodal control of fear-coping strategies by CB₁ cannabinoid receptors.
Metna-Laurent M; Soria-Gómez E; Verrier D; Conforzi M; Jégo P; Lafenêtre P; Marsicano G
J Neurosci; 2012 May; 32(21):7109-18. PubMed ID: 22623656
[TBL] [Abstract][Full Text] [Related]
9. Conditional cannabinoid receptor type 1 mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress responses.
Steiner MA; Marsicano G; Wotjak CT; Lutz B
Psychoneuroendocrinology; 2008 Sep; 33(8):1165-70. PubMed ID: 18653287
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
11. The genetic versus pharmacological invalidation of the cannabinoid CB(1) receptor results in differential effects on 'non-associative' memory and forebrain monoamine concentrations in mice.
Thiemann G; Fletcher BC; Ledent C; Molleman A; Hasenöhrl RU
Neurobiol Learn Mem; 2007 Nov; 88(4):416-23. PubMed ID: 17884611
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors.
Zádor F; Otvös F; Benyhe S; Zimmer A; Páldy E
Neurochem Int; 2012 Aug; 61(3):378-88. PubMed ID: 22613132
[TBL] [Abstract][Full Text] [Related]
13. CB1 cannabinoid receptor-mediated modulation of food intake in mice.
Wiley JL; Burston JJ; Leggett DC; Alekseeva OO; Razdan RK; Mahadevan A; Martin BR
Br J Pharmacol; 2005 Jun; 145(3):293-300. PubMed ID: 15778743
[TBL] [Abstract][Full Text] [Related]
14. Context-specific reversal of cocaine sensitization by the CB1 cannabinoid receptor antagonist rimonabant.
Gerdeman GL; Schechter JB; French ED
Neuropsychopharmacology; 2008 Oct; 33(11):2747-59. PubMed ID: 18059436
[TBL] [Abstract][Full Text] [Related]
15. Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus.
Bambico FR; Cassano T; Dominguez-Lopez S; Katz N; Walker CD; Piomelli D; Gobbi G
Neuropsychopharmacology; 2010 Sep; 35(10):2083-100. PubMed ID: 20571484
[TBL] [Abstract][Full Text] [Related]
16. Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats.
Järbe TU; DiPatrizio NV
Behav Pharmacol; 2005 Sep; 16(5-6):373-80. PubMed ID: 16148441
[TBL] [Abstract][Full Text] [Related]
17. Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain.
Thiemann G; Watt CA; Ledent C; Molleman A; Hasenöhrl RU
Behav Brain Res; 2009 Jun; 200(1):60-7. PubMed ID: 19162082
[TBL] [Abstract][Full Text] [Related]
18. Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.
Järbe TU; LeMay BJ; Vemuri VK; Vadivel SK; Zvonok A; Makriyannis A
Psychopharmacology (Berl); 2011 Aug; 216(3):355-65. PubMed ID: 21369753
[TBL] [Abstract][Full Text] [Related]
19. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor.
Cox ML; Haller VL; Welch SP
Eur J Pharmacol; 2007 Sep; 570(1-3):50-6. PubMed ID: 17588560
[TBL] [Abstract][Full Text] [Related]
20. CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action.
Schlosburg JE; O'Neal ST; Conrad DH; Lichtman AH
Psychopharmacology (Berl); 2011 Aug; 216(3):323-31. PubMed ID: 21340468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
